PDCD1 and small cell lung carcinoma: Therefore, by adjusting for indirect comparisons, we update this NMA to address the distinctions between PD‐1 inhibitors + chemotherapy and PD‐L1 + chemotherapy in the first‐line therapy of ES‐SCLC patients.